Lundbeck Wins FDA Fast Track for Lu AH69593 in Narcolepsy
VALBY, Denmark, July 23, 2026 Lundbeck has received U.S. Food and Drug Administration (FDA) Fast Track designation for Lu...
phase III trial
Advertisement
Royalty Pharma Acquires Cliramitug Royalty Rights from Neurimmune
NEW YORK, July 22, 2026 Royalty Pharma plc has announced the acquisition of a portion of Neurimmune’s royalty interest...
Devonian Begins Pediatric Phase II/III Thykamine Trial
QUÉBEC, Canada, July 21, 2026 Devonian Health Group has received Health Canada authorization to initiate a Phase II/III clinical...
Lundbeck Completes Enrollment in Phase III DEEp OCEAN Trial
VALBY, Denmark, July 20, 2026 H. Lundbeck A/S has reached a major clinical development milestone with the last patient...
REGENXBIO Reports Positive Long-Term Gene Therapy Results
ROCKVILLE, Md., July 18, 2026 REGENXBIO Inc. has announced positive long-term clinical data for its investigational one-time gene therapy,...
Advertisements
Armata Advances AP-SA02 Toward Phase III Bacteremia Trial
LOS ANGELES, July 20, 2026 Armata Pharmaceuticals, Inc. has announced significant clinical, regulatory, manufacturing, and operational progress supporting the...
Nuvation Bio Expands Safusidenib Program with Strong Phase II Data
NEW YORK, July 20, 2026 Nuvation Bio Inc. has announced positive updated Phase II clinical data for safusidenib, its...
Kelun-Biotech Reports Phase III Success for sac-TMT in NSCLC
CHENGDU, China, July 14, 2026 Kelun-Biotech has announced a major clinical milestone after its Phase III OptiTROP-Lung06 trial evaluating...
Lexitas and Ocusun Dose First Patient in Cataract Trial
DURHAM, N.C. & GUANGZHOU, China, July 14, 2026 Lexitas Pharma Services and Ocusun have announced the enrollment of the...
Apnimed Targets First Oral Sleep Apnea Therapy with FDA NDA
CAMBRIDGE, Mass., July 14, 2026 Apnimed, Inc. has achieved a significant regulatory milestone after the U.S. Food and Drug...
Advertisement
